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ASTRACT 
 
As scientists are able to understand and manipulate ever smaller scales of matter, research 
in the fields of biotechnology and nanotechnology has converged to enable such radical 
innovations as lab-on-a-chip devices, targeted drug delivery, and other forms of minimally 
invasive therapy and diagnostics.  This paper provides a descriptive overview of the emerging 
bio-nano sector, identifying what types of firms are entering, from what knowledge base, where 
they are located, and their strategic choices in terms of technological diversity and R&D strategy.  
The firms engaged in bio-nano research and development span the range from start-up firm to 
multinational pharmaceutical, biotech, chemical, and electronics firms:  two thirds of bio-nano 
firms are relatively young and relatively small.   The United States dominates this sector, with 
more than half of all bio-nano firms located in the USA.  Even within this sector which 
epitomizes the convergence of technology, there is a broad range of technological diversity, with 
the most diverse firms overall coming from a base in electronics, the most diverse start-up firms 
coming from a base in nanomaterials, and the most narrowly focused firms coming from a 
biotechnology/pharmaceutical base.  We find that hybridization has been the dominant 
knowledge diversity strategy, with 93% of the bio-nano firms with nano-patents holding multi-
class patents.  
 
INTRODUCTION  
 
Despite the early stage of research and development, the convergence of biotechnology 
and nanotechnology has generated high expectations among national governments and venture 
capital firms. Biotechnology is an established industry and highly research intensive: 
biotechnology and pharmaceutical firms perform approximately 20% of all corporate R&D, 
spending nearly $100 billion on research globally in 2006 (UK Department of Innovation, 
Universities and Skills, 2007).  Nanotechnology is a nascent industry, but one that is also highly 
research intensive and considered commercially promising enough that national governments 
spent nearly $12 billion on nanotechnology R&D in 2008 (Plunkett Research, 2008).  Of the 
approximately 2,500 companies globally involved in nanotechnology research (Lux Research, 
2008), we find that 10% of these firms are conducting bio-nano research – that is, research in 
both biotechnology and nanotechnology.   As scientists are able to understand and manipulate 
ever smaller scales of matter, research in the fields of biotechnology and nanotechnology has 
Page 1 of 12
  
converged to enable such radical innovations as lab-on-a-chip devices, targeted drug delivery, 
and other forms of minimally invasive therapy and diagnostics.  
This bio-nano research has begun to be commercialized, both by incumbent firms and by 
start-up ventures.  Since 2005, nanotechnology venture capital funding has exceeded $500 
million annually in the US (Plunkett Research, 2008).   Bio-nano has been creating 
disproportionate value creation in these start-up ventures, with Jacob Grose of Lux Research 
stating that “Healthcare and life sciences companies have accounted for a staggering $1.68 
billion of the $2.57 billion total valuation of nanotechnology start-ups at IPO” (Nanotechnology 
Now, 2008).  By 2015, bio-nano revenues are forecast to be in the range of $5 billion (Global 
Industry Analysts, Inc., 2010).  Why is there so much excitement about the marriage of 
nanotechnology and biotechnology?  We believe that this is the case because the convergence of 
two technologies generates a multitude of opportunities for radical innovation.   
In this paper, we describe our global sample of bio-nano firms as at 2005 and 2008.  This 
is the first known firm level exploration of all of the firms which have capabilities in both 
biotechnology and nanotechnology.  We describe the size, age, location, and technology 
capabilities of the firms with strengths in both the biomedical sector and the emerging field of 
nanotechnology. We also describe their development of nano-patents over time, and classify 
these patents to establish the dominant areas of technological knowledge they are bringing to this 
nascent bio-nano field.  Further, we develop a range of diversity measures to track their 
technological knowledge diversity, which allows us to investigate technology convergence at the 
firm level. 
Very little has been published in academic journals about the emerging bio-nano 
industry.  Comparisons between the biotechnology and nanotechnology industries have been 
made, including the manner in which incumbent firms innovate in new fields (Rothaermel and 
Thursby, 2007) and the role technical and scientific service firms play in the nanotechnology and 
the biotechnology industries in Italy (Chiaroni et al., 2008).  Specific biomaterial fields have also 
been studied at the firm level (Lysaght and Hazlehurst, 2004).  However, there has only been one 
paper to our knowledge describing the emerging bio-nano sector: a case study approach focusing 
on the knowledge acquisition and integration characteristics of 10 research projects in bio-nano-
technology (Rafols, 2007).  There is a need for an overview of this nascent sector, demonstrating 
how firms are entering, from what knowledge base, with what level of dual competency, and 
with what strategies.  This paper addresses that gap, and, in considering the firm as a unit of 
analysis, and commercialization metrics as dependent variables, attempts to reveal the 
commercialization practices of an emerging field. 
We also add to the recent discussion about emerging industries and technological 
knowledge diversity.  Suzuki and Kodama (2004) analyze the technological diversity over time 
of two large Japanese firms in the electronics and chemical industries, and propose that 
technological diversity aids innovation and firm performance over the long term.  Huang and 
Chen (2010) investigate knowledge diversity of a large sample of firms in the IT sector and 
argue that there is an inverse U relationship between knowledge diversity and innovation 
performance.  Avenel et al. (2007) studied the knowledge diversity strategies by which firms 
enter the multidisciplinary nanotechnology sector.  They argue that convergence at the firm level 
can be achieved through either a strategy of “juxtaposition” where a firm has several independent 
research groups research various technological fields, or one of “hybridization” where a firm has 
forged truly interdisciplinary research groups.  We seek here to depict the technological 
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knowledge diversity strategies employed by firms entering the inherently interdisciplinary bio-
nanotechnology sector.  
 
METHODOLOGY 
 
The data collection sources and methodology are first described, followed by metrics 
utilized to measure the technological capabilities of sample firms and then metrics used to 
investigate knowledge diversity in bio-nano firms. 
 
Data Collection 
Through the use of DMS’s databases “IndustryAnalyzer” and “NewsAnalyzer”1, we have 
identified the global sample of firms with capabilities in both biotechnology and nanotechnology 
at two points in time, 2005 and 2008. As the two DMS databases we used are for firms with 
biomedical capabilities, we searched this database for firms with the following search string: 
“nanomaterials, fullerenes, nanotubes, buckyballs, nanotechnology, or nanoparticles.” This 
enabled us to capture a total of 247 firms with products, services, or research activities in both 
the relatively established biomedical sector and the emerging nanotechnology field.   From these 
databases, we were also able to collect data on each firm’s location, technological capabilities 
and business models.   We examined the 2005 cohort and 2008 cohort of bio-nano firms to draw 
conclusions about firm entry and exit during this time interval.   
We gathered data on the 8,255 US “nano” patents issued by these bio-nano firms up to 
and including patents issued in 2008.  Using the US Patent and Trademark Office website
2
, we 
searched each firm’s patents along with the word (or terms beginning with) “nano” for example, 
“Bayer AND nano”.3  We then searched the resulting patents for false positives, and re-ran the 
search to exclude these.
4
  
When testing for relationships between knowledge diversity and performance, we chose a 
2003 issue date as our cutoff, as we wanted a lag of at least 3 years between the diverse 
knowledge being present in the firm (when the patent was filed) and the output metrics 
measured.  We use this data to calculate knowledge diversity metrics and to classify the 
technological capabilities of the sample firm. Next we gathered data on firm size and growth.  
For the global bio-nano sample obtained, we compiled revenue and employee data from 2004-
2006 through the use of the financial databases MINT Global, Zephyr and Mergent Online, as 
well as Lexis Nexis searches, Standard and Poor’s corporate register, internet searches and direct 
contact with some companies.  When we discovered the vast range of size among the bio-nano 
firms in our sample, we realized that revenue, revenue growth, employment and employment 
growth were not suitable as success metrics, but, rather, as descriptive variables to depict the 
                                                 
1
 http://www.industryanalyzer.com/ 
2
 http://www.uspto.gov/ 
3
 We chose to limit the analysis to patents which mentioned the word nano to make the analysis manageable.  This 
filter does not appear to obscure the firms’ capabilities, as the firm generally files its patents in the area of its 
strongest capabilities.  Many of the firms in the sample patented exclusively in bio and chemistry fields, even when 
we are examining patents that mention “nano”    
4
 We filtered out false positives that referenced only sodium nitrate or sodium nitrite and not extended forms of 
“nano”, while keeping those that referenced either of these chemicals and extended forms of nano, such as “nanom”, 
to re-capture the nanomaterials patents: ((AN/"Bayer" AND nano$) ANDNOT (("NANO.sub.3" OR 
"NANO.sub.2") ANDNOT (((nanom$ OR nanop$) OR nanot$) OR nanos$))) 
Page 3 of 12
  
types of firms entering this emerging sector.  Firm size is also used to differentiate between the 
knowledge diversity strategies of small and large bio-nano firms.  
 
 
Technological Capability Metrics 
We classify the technological capabilities of the firms based on a categorization of their nano-
patent portfolio by patent class.  Every patent is classified into one primary patent class, and may 
include several secondary patent classes, each representing the technological domain the patent 
is related to (e.g., class 977 represents nanotechnology knowledge). Each primary or secondary 
classification is also accompanied by a sub-class, which was not used here (e.g., 977’s sub-class 
734 represents fullerene knowledge). First we classified all of the patent classes into five general 
categories: biology (B), chemistry (C), electronics/physics (P), nanotechnology (N), and other 
(O).
5
 Then we calculated the proportion of (primary and secondary) patent classes used to 
classify the entire bio-nano patent portfolio of each firm according to these categories.  Each firm 
received a ratio of: 
 
                                                
                                                                                 
  (1) 
Technological Knowledge Diversity metrics 
The independent variable that we investigated the most thoroughly was knowledge diversity.  
We created several measures to investigate the knowledge diversity in this bio-nano sample of 
firms.  As a first level examination, we counted the number of nano-patents in each firm’s 
portfolio which were either single-class or multi-class.
6
  In almost half of the nano-patents (40-
50%, depending on timeframe), the same class as mentioned in the primary class was repeated in 
additional secondary classes, resulting in a single-class patent.  Thus, we were able to measure 
how many firms hold a mix of single-class and multi-class patents, and how many firms 
exclusively hold single-class or exclusively multi-class patents.  This count of single- and multi-
class patents gives us a first level indication of whether a firm is combining diverse knowledge in 
their R&D.   
To look more closely at knowledge diversity, and create finer gradations of knowledge 
diversity, we employed an additional type of diversity metrics.  To measure the breadth of the 
nano-patent portfolio of each firm, we created counts of how many different primary patents 
classes were mentioned in the portfolio (Breadth of primary classes) and also how many 
different primary and secondary patent classes were mentioned in the portfolio (Breadth of all 
classes).  The larger the breadth of (primary and secondary) patent classes mentioned, the higher 
the diversity of the patent portfolio.  We also created a simple count of the maximum classes per 
patent, to examine the most diverse patent in a firm’s patent portfolio.   Next we normalized the 
breadth measures by the number of patents held in each firm’s portfolio, resulting in a count of 
the average classes per patent, allowing for the same class to be mentioned multiple times, as 
well as a count of the average unique classes per patent.  Average unique classes per patent is 
                                                 
5
 The categorization we developed is available upon request to the corresponding author.  This classification was 
done independently by three of the authors with acceptable levels of replicability, and we mutually agreed on the 
remaining classes. Each author has at least one technical degree in either biology, materials engineering, or 
mechanical engineering. 
6
 A multi-class patent is one in which the primary and secondary classes mentioned in the patent span more than one 
class.   
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also the metric that Avenel et al. (2007) use to test hybridization in their nanotechnology sample.   
In this paper, we report only on the diversity metrics necessary to demonstrate the technological 
knowledge diversity of these firms involved in bio-nano research. 
 
RESULTS AND DISCUSSION 
 
Bio-nano research and commercialization is not yet widespread but it is growing.  In 2005, there 
were 165 bio-nano firms globally.  By 2008, this number had increased to 221.  There were 82 
new entries into the bio-nano field during this time and 26 exits. To enter the sector, a firm either 
was founded with bio-nano capabilities or an established firm developed bio-nano capabilities.  
About three quarters of these firms are relatively young, and the remaining quarter of the sample 
are incumbent firms extending their capabilities into either biotechnology or nanotechnology.   
As shown in Figure 1, the bio-nano firms in our sample have produced a rapidly 
increasing amount of nano-patents over the past 3 decades, ranging from 80 nano-patents issued 
per year in 1980, to 113 nano-patents per year in 1990, to 355 nano-patents per year in 2000, to 
over 750 nano-patents per year in 2008.  For the bio-nano firms in our sample, 92 firms had 
nano-patents issued as of 2003. The firms’ nano-patent portfolios range from a minimum of zero 
patents to a maximum of 793 patents, with the median number of firm nano-patents being 6.  
This emerging sector was analysed to reveal the defining characteristics of firms in this emerging 
sector: namely, their size, age, location, technological capabilities, technological diversity, 
business models, and clinical focus.  The success of these firms was measured and correlated to 
some of their strategic choices. 
 
 
Figure 1:  Nano-patents over time in our bio-nano sample, categorized by primary class 
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Size, Age and Location 
The sample includes pure play bio-nano startups all the way through to multinational chemical 
and pharmaceutical companies such as Merck and Dow and multinational electronics firms such 
as IBM and Hewlett-Packard.  These firms span the spectrum in size from 1 employee to 
470,000 employees, and from $0 to $92 billion in annual revenues.  Despite this vast range, bio-
nano firms are pre-dominantly young, with nearly three quarters of the sample firms formed 
within the past 2 decades. Bio-nano firms are also predominantly small:  the median annual 
revenue generated by firms in the sample is only $5 million, with the smallest quartile earning 
between $0 and $0.8 million, the largest quartile earning between $270 million and $92 billion, 
and two thirds of the sample firms earning less than $25 million in annual revenues.
7
   The 
median firm size in the sample is approximately 70 employees, with the smallest quartile of the 
firms between 1 and 15 employees, and the largest quartile between approximately 1,800 and 
470,000 employees.  The range of firms involved in bio-nano research is extremely diverse.  
Bio-nano firms range in age (as at 2008) from just formed to the long history of a firm 
formed 340 years previously.  These firms are predominantly new, with the youngest quartile 
from 2 to 8 years of age, and the median age of the bio-nano firms being 12 years.  The 
established incumbent firms are limited to the oldest quartile, which ranges from 22 to 340 years 
of age.   
The US was the dominant country for bio-nano firms throughout the study period, with 
97 US firms identified with bio-nano capabilities as of 2005 and 129 US firms as of 2008, 
remaining relatively constant at 59 % and 58% of the sample respectively.  In fact, the state of 
California alone has more bio-nano firms (28 in 2008) than any other country in the world: thus 
several US States are analyzed as separate regions.  Germany is next at 21 firms, with bio-nano 
firms spread across 19 countries in total.  Table 1 summarizes the location of global bio nano 
firms by region and the changes from 2005 to 2008.  Although the proportion of bio-nano firms 
remained relatively constant by region, within regions the UK had the greatest increase in bio-
nano firms over the interval of observation, moving from 6 to 11 firms.  Asian firms are 
surprisingly underrepresented, although there has been a strong increase from 5 bio-nano firms to 
9 bio-nano firms in Asia over the 3 year interval studied. 
 
 US Europe Austral-Asia ROW Total 
Number of 
Firms in 2005 
97 41 14 13 165 
Number of 
Firms in 2008 
129 57 19 16 221 
Table 1: Location of bio-nano firms: Sample overview 2005 and 2008 
 
Technological Capabilities 
We classified the technological capabilities of the firms in our sample based on a categorization 
of their bio-nano patent portfolio.  Figures 2a and 2b provide an overview of the sample in a 
manner that captures the size of the firms in terms of revenues, the size of their nano-patent 
portfolios, and their technological capabilities in terms of their proportion of biology and 
                                                 
7
 These numbers exclude the firms which did not report revenues.   For 68 of the firms, no 2006 revenue data were 
available. Of the remaining 179 firms that reported revenues, 3 firms reported zero revenues, exactly half reported 
revenues of less than $5 million, and 68 firms (38% of 178) reported more than $25 million in revenues.   
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chemistry as per Equation 1.  The horizontal axis of Figures 2a and 2b ranges from 0% to 100%, 
with 0% representing an absence of biology or chemistry patents in the firm’s portfolio, and 
100% representing solely biology or chemistry patents in the firm’s portfolio. The bubble size 
represents the number of bio-nano patents per firm.    
 
  
 
Figure 2a: Size and technological capabilities of all sample firms with nano-patents 
Figure 2a depicts the entire sample, and demonstrates the broad range of firms entering 
this emerging field, ranging from no revenue up to multinational firms with nearly $100 billion 
in annual revenues.  It is evident that the majority of the firms have their dominant capabilities in 
biology and chemistry fields.   In striking contrast, 4 multinationals (Hewlett-Packard, IBM, 
Philips and Siemens) are approaching nanotechnology research from the physics and 
nanotechnology fields.  Notable dual competency firms include Agilent Tech., Sarnoff, Asahi 
Glass and 3M. 
Figure 2b focuses on the smaller firms in this field, depicting only firms with annual 
revenues less than $25 million.  Many of the small firms in this sector have virtually all of their 
capabilities (as measured by proportion of patents by categorization) in the fields of biology and 
chemistry.
8
  Additionally, all but 4 of the small firms had more than 80% of their capabilities in 
                                                 
8
 To be in the sample, however, the firms have been identified as having capabilities in both bio and nano fields, and 
the patents considered all contain the word “nano” within the text of the patent.  Additionally, to be plotted on 
Figure 2a or 2b, the firms must have at least 1 nano-patent.   
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biology or chemistry.  Thus, most of the small firms in this sector are coming into this sector 
from a biology base, so much so that many had not patented any of their knowledge in the 
nanotechnology, physics, or electronic fields as of 2003.  Only one of the small bio-nano firms in 
the sample is truly a dual capability firm, with patents relatively equally filed in both 
nanotechnology/physics and biology/chemistry fields.  This firm is Luna Innovation, which has a 
division, “Luna Nanoworks” dedicated to “developing pharmaceuticals empowered by carbon 
nanomaterials.”9  
 
  
Figure 2b: Size and technological capabilities of smaller sample firms with nano-patents 
 
Technological Knowledge Diversity 
From the nano-patent portfolios of our bio-nano firms, we first examine how many of their 
patents were classified in a single class versus multiple classes.  These counts can be used as an 
indicator of the R&D strategies of juxtaposition vs. hybridization proposed by Avenel et al. 
(2007). Thus we differentiate “juxtaposition” R&D strategies from “hybridization” strategies, 
with multi-class patents as evidence of multi-disciplinary R&D teams working together 
(hybridization) and single class patents evidence of more narrow and traditionally focused teams 
working independently (juxtaposition). We tracked the evolution of the sample firms’ preference 
for single- vs. multi-class patenting activity for 2003, 2006 and 2008.  
                                                 
9
 http://www.lunananoworks.com/index.asp   (accessed  June 14, 2010) 
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Hybridization is the dominant knowledge diversity strategy, although juxtaposition is 
also employed in some cases by over half of the sample.    Of the 94 bio-nano firms holding 
nano-patents issued during or before 2003, 62 firms (66%) hold single-class nano-patents: of that 
number, 7 firms (7%) hold exclusively single-class nano-patents.  In contrast, there are 87 firms 
(93%) holding multi-class nano-patents, including 32 firms (34%) which hold exclusively multi-
class nano-patents.  Large firms (revenues over $500 million) hold a higher proportion of single 
class patents than smaller firms: 38% of their patents are single class versus 23% for smaller 
firms. 
Over the period of time from 2003 until 2008, hybridization continued to be the norm for 
these bio-nano firms, but the tendency to hold exclusively multi-class nano-patents declined.  Of 
the 138 bio-nano firms holding nano-patents issued during or before 2008, 126 firms (91%) held 
multi-class nano-patents, including 32 firms (23%) which held exclusively multi-class nano-
patents.  In contrast, 106 firms (77%) held single-class nano-patents: of that number, 12 firms 
(9%) held only single-class nano-patents.  This represents an 11% increase in the percentage of 
firms holding single-class nano-patents (juxtaposition strategy). There is also a slight increase in 
the percentage of firms holding exclusively single-class patents (7% to 9%).  This could indicate 
a deliberate shift in R&D strategy over time towards more reliance on juxtaposition. 
Next we employed additional diversity metrics calculated from the patent classifications 
of nano-patents issued from these bio-nano firms.  These metrics are meant to reveal the varying 
degrees of knowledge diversity applied within the bio-nano firms. We expected to find a 
significant amount of diversity in our sample firms, given that they are in an emerging field 
which spans at least 2 previously unrelated areas of knowledge.  This was generally the case, as 
depicted in figures 3a and 3b.  We were also able to observe the range of firm approaches at the 
patent and patent portfolio levels, and note the existence of firms which appear to be extremely 
narrow in their patentable knowledge base.   
In terms of patent counts, the number of different primary classes held in each firm’s 
nano-patent portfolio ranged from a single class up to 78 primary patent classes, with a median 
of 3 primary patent classes represented in a firm’s nano-patent portfolio. The breadth of all 
patent classes held (different primary and secondary classes) held in each firm’s patent portfolio 
ranged from a single class up to 113 patent classes, with a median of 7 patent classes.  Figure 3a 
depicts this diversity metric for the entire sample, along with firm revenues and the size of each 
firm’s nano-patent portfolio, while Figure 3b focuses in on the start-up bio-nano firms.  It is 
evident from Figures 3a and 3b that these measures are strongly correlated to the size of a firm’s 
nano-patent portfolio.  Figure 3a visually highlights the extremely diverse patent portfolios of 
multinational firms with a base in electronics (and some of those with a base in chemicals) and 
the narrow focus of Proctor and Gamble. Figure 3b indicates that start-up nano-materials and 
nano-manufacturing firms are the most diverse, and that the most narrowly focused start-up firms 
have a base in biotechnology and pharmaceuticals. 
The count of unique classes per patent ranged from 1 through 8, with a median of 4, and 
the patent with the maximum unique classes issued was by C-Sixty.  The average count of all 
primary and secondary classes per patent in a firm’s portfolio ranged from 2 through 21, with a 
median of 6.  Our hybridization metric (the average unique classes per patent in a firm’s 
portfolio) ranged from 1 through 6, with a median of 2, again demonstrating the wide range in 
patent diversity in the sample.  Hybridization was highest in the smallest firms (< $5million in 
revenue) and lowest in the largest firms (> 500 million in revenue).  
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Figure 3a:  Diversity of firm nano-patent portfolios: All classes held  
 
  
CONCLUSION 
 
This paper describes the types of firms entering the emerging field of bio-nanotechnology.  
This description of all bio-nano firms globally includes rich data on firm size, location, 
technological capabilities and knowledge diversity. This paper also adds to the discussion of 
technological knowledge diversity in emerging technology sectors and of the R&D strategies 
employed in a sector which embodies technological convergence.   
Our search methodology identified 247 bio-nano firms globally, with 221 bio-nano firms 
remaining active in 2008.  Whereas these firms are spread across 19 countries, the USA 
dominates the emerging field, with 58% of all bio-nano firms based there.  There has been rapid 
growth in knowledge and pre-commercialization ability in this sector, with an eightfold increase 
in nano-patents by our identified global sample of bio-nano firms since the 1980s, and a doubling 
since 2000.  More than half of the bio-nano sector is made up of start-up firms, with the median 
age of firm being 12 years, the median number of employees being 70, and the median revenue 
being $5 million, as at 2006.  Two thirds of the sample firms are relatively small, with annual 
revenues of $25 million or less.  Large multinational pharmaceutical, chemical, and electronics 
firms also play a significant role in the sector, with a dominant position in nano patents, and take 
different approaches into the bio-nano sector.   
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Figure 3b:  Diversity of start-up firm nano-patent portfolios: All classes held 
 
 
Our sample and analysis show that the bio-nano sector is emerging predominantly from 
firms with biology and chemistry capabilities, which have ventured into nanotechnology.  This 
trend is particularly notable with start-up firms: most of the smaller firms in the sample patent 
heavily, and many exclusively, in biological and chemical fields.  There are also four electronics 
multinationals which have predominantly physics, electronics, and nanotechnology capabilities: 
Hewlett-Packard, IBM, Philips and Siemens. 
The firms have a great range in knowledge diversity, even within this sector of 
technological convergence.  Of the 92 firms which had issued nano-patents as of 2003, 60 firms 
issued at least one single-class patent (not diverse) and 85 firms issued at least one multi-class 
patent.  Only seven firms held solely single-class patents (and five of those seven firms held only 
a single nano-patent) and a considerable 32 firms held solely multi-class patents, albeit with 
small patent portfolios.  The least technologically diverse (i.e., more focused) firms with more 
than one patent were Proctor and Gamble and the biotechnology venture, CombiMatrix.  The 
most technologically diverse firm overall was Hewlett-Packard.  The start-up firm, C-Sixty, held 
the most diverse multi-class patent spanning 8 classes. 
Thus hybridization has been the dominant knowledge diversity strategy, with 93% of the 
bio-nano firms with nano-patents holding multi-class patents and 35% of the bio-nano firms 
holding exclusively multi-class patents as of 2003.  Over the period of time from 2003 until 
2008, hybridization continued to be the norm for these bio-nano firms, but the tendency to issue 
exclusively multi-class patents declined.  Large firms held a larger percentage of single class 
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patents than small firms, and large firms referenced fewer unique classes per patent than smaller 
firms.  
The bio-nano firms with the greatest knowledge diversity overall are multinational 
electronics and chemical firms.  Large multinational firms in general have a strikingly higher 
portfolio diversity than smaller firms and are more likely to achieve that diversity through a 
juxtaposition strategy.  Of the start-up bio-nano firms, we find that the most diverse are those 
with a base in nanomaterials and the most narrowly focused are coming from a base of 
biotechnology and pharmaceuticals. These diversity metrics are valuable in showing a range of 
approaches to competing in an emerging sector at the convergence of two fields of knowledge. 
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